ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,067.41
0.44%
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs Yen
155.775
0.00%
Brent Oil
82.585
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) ニュース

OLMA

Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:OLMA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0905 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0905 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0905 : 02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0820 : 02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0806 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0705 : 00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0305 : 37GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/05/0120 : 02GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in MayNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/04/0905 : 30GlobeNewswire Inc.Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/04/0305 : 29GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/1205 : 31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/1205 : 15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/1205 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/1205 : 03GlobeNewswire Inc.Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/0621 : 03GlobeNewswire Inc.Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/0507 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/0506 : 30GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/03/0104 : 26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/1506 : 08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/1502 : 53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/1307 : 16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/1214 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0621 : 01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0607 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0607 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0607 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0307 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0306 : 30GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0205 : 24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
2024/02/0106 : 21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OLMA

最近閲覧した銘柄

USI
USTECH100
US Tech 100
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US500
US 500
NASDAQ
AMZN
Amazon.com
CCOM
SILVER
SILVER
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
COIN
SOLUSD
Solana
NASDAQ
TSLA
Tesla
NASDAQ
AAPL
Apple
FX
USDGBP
US Dollar vs Sterling
AMEX
XLV
Health Care Select Sector
NYSE
MRK
Merck
AMEX
SPY
SPDR S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有